Khondrion (a spin-off of the Radboudumc), a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces the publication of new research in PLOS ONE. They examined the in vivo active metabolite of sonlicromanol, as a selective inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1)-mediated PGE2 synthesis in prostate cancer stem cells and its potential as a novel treatment approach for prostate cancer and other cancers with high mPGES-1 expression.
Sonlicromanol (KH176) is Khondrion’s wholly-owned investigational lead asset, currently in phase IIb development as a potentially disease-modifying treatment for mitochondrial disease. The company has previously demonstrated the ability of sonlicromanol’s active metabolite to selectively inhibit mPGES-1, a key enzyme involved in the production of prostaglandin E2. This prostaglandin, known to induce and propagate the inflammation response, was found in significantly increased levels in cells derived from mitochondrial disease patients. Importantly, the aggressiveness of cancers, like prostate cancer, has also been found in independent studies to be associated with elevated expression of mPGES-1.
The new research, authored by Khondrion, details the effects of selective mPGES-1 targeting by sonlicromanol’s active metabolite, and examines its potential to decrease the aggressiveness of prostate cancer by inhibiting mPGES-1 expression.
The research team found that inhibition of mPGES-1 by sonlicromanol’s metabolite was able to considerably reduce spheroid growth in the human prostate cancer cell line DU145, potentially offering a novel approach in treating prostate cancer and other malignancies with high expression of mPGES-1. Sonlicromanol’s active metabolite was found to reduce the constitutively high mPGES-1 levels. The growth of spheroids in a physiological relevant 3D environment for tumour cells was reduced and the prostate cancer stem cell population was selectively decreased. These findings are of particular interest as they further strengthen earlier research indicating the potential of sonlicromanol as a treatment for patients with high mPGES-1 expression and signal its potential as an anti-tumour drug, based on its ability to decrease the size of cancer stem cell-formed spheroids.
Related news items
Differences in the number of de novo mutations between individuals due to small family-specific effects and stochasticity28 July 2021
Christian Gilissen and colleagues investigated whether there is a family-specific contribution to the number of de novo mutations in the DNA of offspring and published the results in the Genome Research.read more
Christa Sperna Weiland, Erwin van Geenen and Joost Drenth discuss the best strategy to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis28 July 2021
Christa Sperna Weiland, Erwin van Geenen and Joost Drenth, published in Lancet Gastroenterology & Hepatology a systematic review and network meta-analysis to determine the most efficacious prophylaxis strategy to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis.read more
ZonMw Gender in Research competition awarded to Genderful Research World Consortium27 July 2021
Natalia Valdrighi and Esmeralda Blaney Davidson won the competition to create a plan for the dissemination of the knowledge and skills gained during the Gender in Research workshop amongst their peers, colleagues and institution, financed by ZonMw and CIHR-IGH in Canada.read more
Young people with colorectal cancer deserve their own treatment27 July 2021
Richarda de Voer and Marjolijn Ligtenberg's study on clinical, pathological, genetic and molecular characteristics of colorectal tumors in adolescents and adults 25 years of age or younger is published in Clinical Gastroenterology and Hepatology.read more
Nijmegen literally puts Digital Health on the map Flourishing ecosystem gets its own interactive overview22 July 2021
Digital Health is thriving in the Nijmegen region, where it contributes to better care and health and also creates jobs. To bring developers and end users even closer together, The Economic Board and the Radboudumc are introducing the Interactive Digital Health map.read more